Additional file 1 of Beneficial effects of the combination of BCc1 and Hep-S nanochelating-based medicines on IL-6 in hospitalized moderate COVID-19 adult patients: a randomized, double-blind, placebo-controlled clinical trial
Additional file 1: Table S A) Descriptive Statistics of cell blood count by Group (nanomedicines vs. Placebo). B) Tests of Within-Subjects Effects. The blood samples were taken and analyzed on day zero, at discharge, and at the end of the treatment (on day 28). The results indicated that all the measured parameters were at normal range on day 28, and there was no significant difference between the treatment and placebo groups
